A Phase 3, Randomized Study of Adjuvant Immunotherapy With Nivolumab Combined With Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma.
Phase of Trial: Phase III
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms CheckMate 915
- Sponsors Bristol-Myers Squibb
- 10 Apr 2017 Status changed from not yet recruiting to recruiting.
- 20 Mar 2017 Planned End Date changed from 1 Jan 2023 to 20 Jan 2023.
- 20 Mar 2017 Planned primary completion date changed from 1 Dec 2020 to 9 Dec 2020.